CARMEN II期试验:HIV相关高危伯基特淋巴瘤的剂量密集型短程治疗
CARMEN是一项多中心II期试验,评估36天诱导化疗后大剂量阿糖胞苷巩固及BEAM方案自体干细胞移植治疗HIV阳性高危伯基特淋巴瘤或高级别B细胞淋巴瘤。20例可评估患者中13例诱导后完全缓解,总缓解率90%,5年无进展生存70%、总生存75%,安全性优于既往方案。
要点
- 36天剂量密集诱导方案在HIV相关高危伯基特淋巴瘤中安全且有效。
- 诱导后完全缓解13/20例,总缓解率90%(95%CI 77-100)。
- 5年无进展生存70%(95%CI 60-80%),总生存75%(95%CI 66-84%)。
核心结论
- 该36天剂量密集短程方案在HIV阳性高危伯基特淋巴瘤或高级别B细胞淋巴瘤患者中安全且有效,达到主要终点。
- 与既往方案相比,该方案疗程更短,在维持疗效的同时改善了耐受性。
研究设计与样本
- 多中心II期试验,纳入20例可评估的HIV阳性成人患者,中位年龄42岁(范围26-58),16例男性。
- 患者包括未经治疗的伯基特淋巴瘤16例、高级别B细胞淋巴瘤3例、双打击淋巴瘤1例,均有高危特征,其中脑膜浸润5例、骨髓浸润9例。
- 实验方案包括36天多药联合诱导化疗、大剂量阿糖胞苷为基础的巩固治疗及根据反应调整的BEAM方案(卡莫司汀、依托泊苷、阿糖胞苷、美法仑)预处理自体干细胞移植。
- 主要终点为20例可评估患者中诱导后至少11例完全缓解。
主要发现
- 诱导后(中位 duration 47天,四分位距41-54)完全缓解13例、部分缓解5例,总缓解率90%(95%CI 77-100)。
- 仅2例发生4级非血液学毒性(肝毒性和黏膜炎),无系统性真菌感染病例;2例死于毒性(细菌感染)。
- 中位随访55个月(范围41-89),14例无复发、15例存活,5年无进展生存70%(95%CI 60-80%)、总生存75%(95%CI 66-84%)。
- 所有缓解者均接受巩固治疗,其中5例需自体干细胞移植;无脑脊液/脑膜淋巴瘤患者出现中枢神经系统复发。
关键数值与推荐
- 主要终点为20例可评估患者中诱导后完全缓解≥11例。
- 诱导后总缓解率90%(95%CI 77-100),完全缓解13例。
- 5年无进展生存70%(95%CI 60-80%),总生存75%(95%CI 66-84%)。
临床怎么用
- 该短程剂量密集方案可作为HIV阳性高危伯基特淋巴瘤或高级别B细胞淋巴瘤的一种治疗选择。
- 治疗过程中需关注细菌感染和肝毒性、黏膜炎等非血液学毒性。
- 脑膜浸润患者接受该方案后未出现中枢神经系统复发。
局限性
- 样本量小(20例可评估),为非随机单臂II期试验。
- 随访时间有限,中位55个月。
- 结果需在更大规模研究中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A few prospective trials in HIV-positive patients with Burkitt lymphoma (BL) or high-grade B-cell lymphoma (HGBL) have been reported. Investigated therapies have shown good efficacy but relevant safety problems, with high rates of interruptions, severe mucositis, septic complications, and fungal infections. Here, we report the results of a multicentre phase II trial addressing a new dose-dense, short-term therapy aimed at maintaining efficacy and improving tolerability. The experimental programme included a 36-day polychemotherapy induction followed by high-dose cytarabine-based consolidation and response-tailored BEAM (carmustine, etoposide, cyatarabine, and melphalan)- conditioned autologous stem cell transplantation (ASCT). This therapy would be considered active if ≥11 complete remissions (CR) after induction (primary endpoint) were recorded among 20 assessable patients. HIV-positive adults (median age 42, range 26-58; 16 males) with untreated BL (n = 16), HGBL (n = 3) or double-hit lymphoma (n = 1) were enrolled. All patients had high-risk features, with meningeal and bone marrow infiltration in five and nine patients respectively. The experimental programme was safe and active in a multicentre setting, with only two episodes of grade 4 non-haematological toxicity (hepatotoxicity and mucositis), and no cases of systemic fungal infections; two patients died of toxicity (bacterial infections). Response after induction (median duration: 47 days; interquartile range 41-54), was complete in 13 patients and partial in five [overall response rate = 90%; 95% confidence interval (CI) = 77-100]. All responders received consolidation, and five required autologous stem cell transplant. At a median follow-up of 55 (41-89) months, 14 patients are relapse-free and 15 are alive, with a five-year progression-free survival and an overall survival of 70% (95% CI = 60-80%) and 75% (95% CI = 66-84) respectively. No patient with cerebrospinal fluid (CSF)/meningeal lymphoma experienced central nervous system recurrence. With respect to previously reported regimens, this programme was delivered in a shorter period, and achieved the main goal of maintaining efficacy and improving tolerability.
引用
- Ferreri AJM, Cattaneo C, Lleshi A, et al. A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the "CARMEN" phase II trial. Br J Haematol. 2020. PMID: 33085777. doi:10.1111/bjh.17188
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。